Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Darzalex
Pharma
J&J angles Darzalex for first move into early-stage myeloma
With a positive phase 3 readout, J&J has filed Darzalex for potential U.S. and EU approvals as the first treatment for smoldering multiple myeloma.
Angus Liu
Nov 8, 2024 9:53am
J&J leans on oncology growth drivers as Stelara sales slow
Oct 15, 2024 11:45am
Sponsored
GSK's ADC Blenrep delivers survival win against J&J's Darzalex
Nov 14, 2024 9:24am
J&J counters Sanofi's Sarclisa nod with Darzalex data drop
Sep 27, 2024 3:59pm
Sanofi moves on J&J's Darzalex in first-line myeloma with FDA nod
Sep 20, 2024 4:06pm
With FDA nod, J&J touts new 'foundational' multiple myeloma combo
Jul 31, 2024 10:39am
